These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 23578545)
1. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents. Huang Q; Wang L; Lu W Eur J Med Chem; 2013 May; 63():746-57. PubMed ID: 23578545 [TBL] [Abstract][Full Text] [Related]
2. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors. Miao Z; Zhu L; Dong G; Zhuang C; Wu Y; Wang S; Guo Z; Liu Y; Wu S; Zhu S; Fang K; Yao J; Li J; Sheng C; Zhang W J Med Chem; 2013 Oct; 56(20):7902-10. PubMed ID: 24069881 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents. Zhu L; Zhuang C; Lei N; Guo Z; Sheng C; Dong G; Wang S; Zhang Y; Yao J; Miao Z; Zhang W Eur J Med Chem; 2012 Oct; 56():1-9. PubMed ID: 23084702 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of new homocamptothecin analogs. Luo Y; Yu S; Tong L; Huang Q; Lu W; Chen Y Eur J Med Chem; 2012 Aug; 54():281-6. PubMed ID: 22647222 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of novel benzoxanthone analogues as non-Camptothecin topoisomerase I inhibitors. Cheng P; Zhu L; Guo W; Liu W; Yao J; Dong G; Zhang Y; Zhuang C; Sheng C; Miao Z; Zhang W J Enzyme Inhib Med Chem; 2012 Jun; 27(3):437-42. PubMed ID: 21770860 [TBL] [Abstract][Full Text] [Related]
6. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Evaluation of 10-Substituted Camptothecin Derivatives with Improved Water Solubility and Activity. Yang XY; Zhao HY; Lei H; Yuan B; Mao S; Xin M; Zhang SQ ChemMedChem; 2021 Mar; 16(6):1000-1010. PubMed ID: 33241878 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity evaluation of a novel series of camptothecin analogs. Lv J; Guo N; Wen SP; Teng YO; Ma MX; Yu P J Asian Nat Prod Res; 2013; 15(8):867-74. PubMed ID: 23796391 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity. Yao L; Zhao X; Li Q; Zu Y; Fu Y; Zu B; Meng X; Liu C Int J Pharm; 2012 Feb; 423(2):586-8. PubMed ID: 22193057 [TBL] [Abstract][Full Text] [Related]
10. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors. Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological assays of E-ring analogs of camptothecin and homocamptothecin. Tangirala RS; Antony S; Agama K; Pommier Y; Anderson BD; Bevins R; Curran DP Bioorg Med Chem; 2006 Sep; 14(18):6202-12. PubMed ID: 16793274 [TBL] [Abstract][Full Text] [Related]
14. An overview on the development of new potentially active camptothecin analogs against cancer. Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593 [TBL] [Abstract][Full Text] [Related]
15. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells. Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225 [TBL] [Abstract][Full Text] [Related]
16. Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation. Li M; Ye W; Fu K; Zhou C; Shi Y; Huang W; Chen W; Hu J; Jiang Z; Zhou W Eur J Med Chem; 2020 Sep; 202():112509. PubMed ID: 32668379 [TBL] [Abstract][Full Text] [Related]
18. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Lesueur-Ginot L; Demarquay D; Kiss R; Kasprzyk PG; Dassonneville L; Bailly C; Camara J; Lavergne O; Bigg DC Cancer Res; 1999 Jun; 59(12):2939-43. PubMed ID: 10383158 [TBL] [Abstract][Full Text] [Related]
19. Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study. Van HT; Cho WJ Bioorg Med Chem Lett; 2009 May; 19(9):2551-4. PubMed ID: 19328687 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of new camptothecin analogs with improved antitumor activities. Niizuma S; Tsukazaki M; Suda H; Murata T; Ohwada J; Ozawa S; Fukuda H; Murasaki C; Kohchi M; Morikami K; Yoshinari K; Endo M; Ura M; Tanimura H; Miyazaki Y; Takasuka T; Kawashima A; Nanba E; Nakano K; Ogawa K; Kobayashi K; Okabe H; Umeda I; Shimma N Bioorg Med Chem Lett; 2009 Apr; 19(7):2018-21. PubMed ID: 19254843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]